Abstract:Abstract Background Multiple sclerosis (MS) is one of the most common autoimmune disorders characterized by the infiltration of immune cells into the brain and demyelination. The unwanted immunosuppressive side effect of therapeutically successful natalizumab led us to focus on the choroid plexus (CP), a key site for the first wave of immune cell infiltration in experimental autoimmune encephalomyelitis (EAE), for the control of immune cells trafficking. Adenosine A 2A receptor (A 2A R) is emerging as a potential pharmacological target to control EAE pathogenesis. However, the cellular basis for the A 2A R-mediated protection remains undetermined. Methods In the EAE model, we assessed A 2A R expression and leukocyte trafficking determinants in the CP by immunohistochemistry and qPCR analyses. We determined the effect of the A 2A R antagonist KW6002 treatment at days 8–12 or 8–14 post-immunization on T cell infiltration across the CP and EAE pathology. We determined the critical role of the CP-A 2A R on T cell infiltration and EAE pathology by focal knock-down of CP-A 2A R via intracerebroventricular injection of CRE-TAT recombinase into the A 2A R flox/flox mice. In the cultured CP epithelium, we also evaluated the effect of overexpression of A 2A Rs or the A 2A R agonist CGS21680 treatment on the CP permeability and lymphocytes migration. Results We found the specific upregulation of A 2A R in the CP associated with enhanced CP gateway activity peaked at day 12 post-immunization in EAE mice. Furthermore, the KW6002 treatment at days 8–12 or 8–14 post-immunization reduced T cell trafficking across the CP and attenuated EAE pathology. Importantly, focal CP-A 2A R knock-down attenuated the pathogenic infiltration of Th17 + cells across the CP via inhibiting the CCR6–CCL20 axis through NFκB/STAT3 pathway and protected against EAE pathology. Lastly, activation of A 2A R in the cultured epithelium by A 2A R overexpression or CGS21680 treatment increased the permeability of the CP epithelium and facilitated lymphocytes migration. Conclusion These findings define the CP niche as one of the primary sites of A 2A R action, whereby A 2A R antagonists confer protection against EAE pathology. Thus, pharmacological targeting of the CP-A 2A R represents a novel therapeutic strategy for MS by controlling immune cell trafficking across CP.

Blocking Initial Infiltration of Pioneer Cd8(+) T-Cells into the Cns Via Inhibition of Shp-2 Ameliorates Experimental Autoimmune Encephalomyelitis in Mice

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Dose-dependent anti-inflammatory and neuroprotective effects of an α β 3 integrin-binding peptide

The Protective Effect of Astragalus Polysaccharide on Experimental Autoimmune Encephalomyelitis in Mice by Activating the AMPK/JAK/STAT3/Arginase-1 Signaling Pathway

Combination of Apoptotic T Cell Induction and Self-Peptide Administration for Therapy of Experimental Autoimmune Encephalomyelitis

Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis

The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.

MAP kinase inhibitor PD98059 regulates Th1, Th9, Th17, and natural T regulatory cells in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis

Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration

Cd8 Alpha+ Dendritic Cells And Immune Protection From Experimental Allergic Encephalomyelitis

Targeting CB2 receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis

Neuroprotective effects of a novel peptide through the Rho-integrin-Tie2 and PI3K/Akt pathways in experimental autoimmune encephalomyelitis model

High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis

Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis

A Camelid-Derived STAT-Specific Nanobody Inhibits Neuroinflammation and Ameliorates Experimental Autoimmune Encephalomyelitis (EAE)

CCDC134 Ameliorated Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells

Effect of a Cyclic Heptapeptide Based on the Human CD4 Domain 1 CC′ Loop Region on Murine Experimental Allergic Encephalomyelitis: Inhibition of Both Primary and Secondary Responses

Astragalus polysaccharides promote neural stem cells-derived oligodendrogenesis through attenuating CD8 + T cell infiltration in experimental autoimmune encephalomyelitis

Non-saponin from Panax ginseng maintains blood-brain barrier integrity by inhibiting NF-κB and p38 MAP kinase signaling pathways to prevent the progression of experimental autoimmune encephalomyelitis